ArticleThe Pan African medical journal2025
Predictive factors of radioactive iodine therapy failure in hyperthyroidism: a retrospective study of 171 patients.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: radioiodine therapy with iodine-131 is a standard treatment for hyperthyroidism. Nevertheless, the variability in individual response underscores the need to identify reliable predictors of treatment failure. The study aimed to determine the clinical and biological factors associated with the failure of the first course of radioactive iodine therapy in hyperthyroid patients. Methods: this was a retrospective cohort study conducted between 2012 and 2018, including 171 patients treated for hyperthyroidism with radioiodine therapy at the Salah Azaiez Institute. Demographic, clinical, biological, and therapeutic data were collected and analysed. Results: the median age was 49 years, with a female predominance (sex ratio: 0.41). Graves' disease accounted for 73.7% of cases, and resistance to antithyroid drugs was the main indication for radioiodine therapy (68%). A fixed dose of iodine-131 was administered (mean: 14 ± 2.6 mCi). Treatment failure after the first course occurred in 22.2% of patients (n=38). Failure was significantly associated with higher administered doses (p=0.007), TSH receptor antibody positivity (p=0.005), and the presence of ophthalmopathy (p=0.013). Conclusion: failure after radioiodine therapy appears to be influenced by biological markers (TSH receptor antibodies) and specific clinical factors (ophthalmopathy). These results support individualised dosing strategies and highlight the need for multicenter studies to standardise treatment protocols in nuclear medicine centers in Tunisia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.